Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

858
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
858
Antibody Actions01:26

Antibody Actions

1.1K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.1K
Antibody Structure01:10

Antibody Structure

59.6K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
59.6K
Cells of the Innate Immune Response01:28

Cells of the Innate Immune Response

1.6K
The innate immune response is an immediate and non-specific response against pathogens, acting swiftly to prevent the spread of infections. The primary cells involved in this response are phagocytes and natural killer (NK) cells.
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
1.6K
Transcytosis of IgG01:15

Transcytosis of IgG

2.7K
Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
2.7K
Immunoglobulin-like Cell Adhesion Molecules01:31

Immunoglobulin-like Cell Adhesion Molecules

3.2K
Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhancing IgG fragment crystallizable sialylation improves the therapeutic activity of IL-23 cytokine blockade.

JCI insight·2026
Same author

Type I IFN-dependent FcγRIV signaling in murine monocytes promotes lethal anaphylaxis during viral infections.

The Journal of clinical investigation·2026
Same author

Efficacy and safety of eltrombopag in combination with dexamethasone as first-line treatment in adult patients with newly diagnosed immune thrombocytopenia.

British journal of haematology·2026
Same author

High pretreatment peripheral blood T-cell receptor clonality as a predictor of prolonged response in immune thrombocytopenia.

British journal of haematology·2026
Same author

GM-CSF and specific type 2 cytokines induce CD103<sup>+</sup> and CD301b<sup>+</sup> cell states in cDC1s and cDC2s.

Cell reports·2025
Same author

Macrophages foster anti-tumor immunity by ZEB1-dependent cytotoxic T cell chemoattraction.

Communications biology·2025

Related Experiment Video

Updated: Jun 13, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K

Cytotoxic IgG: Mechanisms, functions, and applications.

Miriam Wöhner1, Falk Nimmerjahn1

  • 1Division of Genetics, Department of Biology, Friedrich Alexander University Erlangen-Nürnberg, Erwin Rommelstr. 3, 91058 Erlangen, Germany.

Immunity
|June 11, 2025
PubMed
Summary

Immunoglobulin G (IgG) antibodies trigger antibody-dependent cellular cytotoxicity (ADCC) to eliminate target cells. This review explores ADCC pathways and their impact on improving antibody therapies for diseases.

Keywords:
Fcgamma receptorautoimmunitycancercytotoxic antibodyimmunoglobulin G

More Related Videos

Determining the Phagocytic Activity of Clinical Antibody Samples
09:05

Determining the Phagocytic Activity of Clinical Antibody Samples

Published on: November 30, 2011

23.5K
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

8.6K

Related Experiment Videos

Last Updated: Jun 13, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K
Determining the Phagocytic Activity of Clinical Antibody Samples
09:05

Determining the Phagocytic Activity of Clinical Antibody Samples

Published on: November 30, 2011

23.5K
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

8.6K

Area of Science:

  • Immunology
  • Molecular Biology
  • Therapeutic Antibody Development

Background:

  • Immunoglobulin G (IgG) antibodies are crucial for eliminating target cells via antibody-dependent cellular cytotoxicity (ADCC).
  • Cytotoxic antibodies are established therapies for malignant, autoimmune, and infectious diseases.
  • Current therapeutic efficacy of cytotoxic antibodies is often limited, with optimization strategies showing modest improvements.

Purpose of the Study:

  • To review the complex molecular and cellular mechanisms of ADCC reactions.
  • To analyze how target cell type, effector cells, and tissue microenvironment influence ADCC.
  • To discuss strategies for enhancing therapeutic efficacy and present an updated model of IgG-mediated cytotoxicity.

Main Methods:

  • Literature review of ADCC pathways and mechanisms.
  • Analysis of factors affecting ADCC in various disease contexts.
  • Synthesis of current knowledge to propose an updated model.

Main Results:

  • ADCC is a multifaceted process influenced by intricate interactions between antibodies, target cells, effector cells, and the tissue environment.
  • Understanding these interactions is key to overcoming limitations in current antibody therapies.
  • Existing optimization approaches have yielded limited success in enhancing therapeutic outcomes.

Conclusions:

  • A comprehensive understanding of ADCC pathways is essential for developing more effective antibody-based therapeutics.
  • Modulating the interplay between target cells, effector cells, and the microenvironment holds promise for improving ADCC efficacy.
  • An updated model of cytotoxic IgG activity is proposed to guide future therapeutic development.